109 related articles for article (PubMed ID: 19777250)
21. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
22. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
23. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer.
Han SS; Lee SH; Kim DH; Kim JW; Park NH; Kang SB; Song YS
Acta Obstet Gynecol Scand; 2010; 89(2):168-74. PubMed ID: 19916890
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
26. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy.
Koper NP; Massuger LF; Thomas CM; Kiemeney LA; Verbeek AL
Anticancer Res; 1998; 18(3B):1897-902. PubMed ID: 9677441
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of RCAS1 as a biomarker of uterine cancer.
Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H
Gynecol Oncol; 2006 Dec; 103(3):924-31. PubMed ID: 16842844
[TBL] [Abstract][Full Text] [Related]
28. Serum sex hormones and breast cancer risk factors in postmenopausal women.
Lamar CA; Dorgan JF; Longcope C; Stanczyk FZ; Falk RT; Stephenson HE
Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):380-3. PubMed ID: 12692114
[TBL] [Abstract][Full Text] [Related]
29. Ovarian stromal hyperplasia and ovarian vein steroid levels in relation to endometrioid endometrial cancer.
Jongen VH; Hollema H; van der Zee AG; Santema JG; Heineman MJ
BJOG; 2003 Jul; 110(7):690-5. PubMed ID: 12842061
[TBL] [Abstract][Full Text] [Related]
30. Association between adiponectin, insulin resistance, and endometrial cancer.
Soliman PT; Wu D; Tortolero-Luna G; Schmeler KM; Slomovitz BM; Bray MS; Gershenson DM; Lu KH
Cancer; 2006 Jun; 106(11):2376-81. PubMed ID: 16639730
[TBL] [Abstract][Full Text] [Related]
31. Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients.
Lawicki S; Będkowska GE; Gacuta-Szumarska E; Szmitkowski M
Growth Factors; 2012 Feb; 30(1):29-36. PubMed ID: 22010785
[TBL] [Abstract][Full Text] [Related]
32. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
33. [Autoantibodies to steroid-producing ovarian cells in cancer patients].
Bershteĭn LM; Poroshina TE; Vasil'ev DA; Orlova AV
Vopr Onkol; 2008; 54(5):602-5. PubMed ID: 19069474
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.
Saarelainen SK; Peltonen N; Lehtimäki T; Perheentupa A; Vuento MH; Mäenpää JU
Am J Obstet Gynecol; 2013 Aug; 209(2):142.e1-6. PubMed ID: 23583212
[TBL] [Abstract][Full Text] [Related]
35. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of the tumor markers in the diagnosis of idiopathic deep venous thrombosis associated cancer].
Enguídanos MJ; Todolí JA; Saro E; Salvador G; Villar J; Gómez-Biedma S; Micó L; Calabuig JR
An Med Interna; 2002 Nov; 19(11):561-6. PubMed ID: 12522891
[TBL] [Abstract][Full Text] [Related]
37. Significance of laboratory studies for ruling out metastases in primary endometrial carcinoma.
Heyer H; Grunwald S; Köhler G; Ohlinger R
Anticancer Res; 2007; 27(3B):1673-7. PubMed ID: 17595795
[TBL] [Abstract][Full Text] [Related]
38. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
Farias-Eisner G; Su F; Robbins T; Kotlerman J; Reddy S; Farias-Eisner R
Am J Obstet Gynecol; 2010 Jan; 202(1):73.e1-5. PubMed ID: 19766980
[TBL] [Abstract][Full Text] [Related]
39. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer.
Hsing AW; Comstock GW
Cancer Epidemiol Biomarkers Prev; 1993; 2(1):27-32. PubMed ID: 8420607
[TBL] [Abstract][Full Text] [Related]
40. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
